Literature DB >> 10721780

Fludarabine containing-regimens may adversely affect peripheral blood stem cell collection in low-grade non Hodgkin lymphoma patients.

D Laszlo1, P Galieni, D Raspadori, G Scalia, C Bigazzi, M Bocchia, A Bucalossi, G Marotta, M Tozzi, F Lauria.   

Abstract

Fludarabine (FLUDA) based chemotherapy has shown promise in both initial and salvage treatment of low-grade non Hodgkin's lymphomas (LG-NHL). Recently, more aggressive therapies followed by autologous hemopoietic progenitor cell rescue, have also been successfully employed in these patients. However, this procedure, due to several factors including previous therapeutic regimens, is often limited by an inadequate collection of peripheral blood stem cell (PBSC). At present, very little data is available on the effect of FLUDA containing regimens in PBSC collection. We report our preliminary experience showing a possible correlation between FLUDA based chemotherapy regimens employed before mobilization and inability to collect an adequate number of blood derived hematopoietic progenitors for autologous PBSC transplantation in LG-NHL patients.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10721780     DOI: 10.3109/10428190009057639

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  4 in total

1.  Prolonged myelosuppression with clofarabine in the treatment of patients with relapsed or refractory, aggressive non-Hodgkin lymphoma.

Authors:  Kristie A Blum; Mehdi Hamadani; Gary S Phillips; Gerard Lozanski; Amy J Johnson; David M Lucas; Lisa L Smith; Robert Baiocchi; Thomas S Lin; Pierluigi Porcu; Steven M Devine; John C Byrd
Journal:  Leuk Lymphoma       Date:  2009-03

2.  Results of a randomized trial comparing high-dose chemotherapy plus Auto-SCT and R-FC in CLL at diagnosis.

Authors:  M Magni; M Di Nicola; C Patti; R Scimè; A Mulè; A Rambaldi; T Intermesoli; P Viero; C Tarella; A Gueli; L Bergui; L Trentin; A Barzan; F Benedetti; A Ambrosetti; F Di Raimondo; A Chiarenza; G Parvis; A Billio; I Attolico; A Olivieri; M Montanari; C Carlo-Stella; P Matteucci; L Devizzi; A Guidetti; S Viviani; P Valagussa; A M Gianni
Journal:  Bone Marrow Transplant       Date:  2014-01-20       Impact factor: 5.483

Review 3.  Management of indolent lymphoma: where are we now and where are we going.

Authors:  Matthew A Lunning; Julie M Vose
Journal:  Blood Rev       Date:  2012-10-09       Impact factor: 8.250

4.  Rituximab-Induced Splenic Rupture and Cytokine Release.

Authors:  Ranjit Nair; Shereen Gheith; Nicholas Lamparella
Journal:  Am J Case Rep       Date:  2016-03-14
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.